Genmab A/S's (GMAB) "Buy" Rating Reiterated at HC Wainwright

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $50.00 price target on the stock. HC Wainwright's target price suggests a potential upside of 134.92% from the stock's previous close.

Other analysts also recently issued research reports about the stock. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. BMO Capital Markets reiterated an "outperform" rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Redburn Atlantic began coverage on Genmab A/S in a research note on Tuesday, October 8th. They set a "buy" rating on the stock. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Genmab A/S currently has an average rating of "Moderate Buy" and an average price target of $45.20.

Genmab A/S Stock Up 1.5 %

Shares of Genmab A/S stock traded up $0.31 on Thursday, hitting $21.28. The stock had a trading volume of 600,752 shares, compared to its average volume of 1,087,094. The stock has a market cap of $14.09 billion, a price-to-earnings ratio of 20.67, a price-to-earnings-growth ratio of 0.59 and a beta of 0.97. The business's 50 day moving average is $21.07 and its two-hundred day moving average is $23.98. Genmab A/S has a twelve month low of $19.85 and a twelve month high of $31.88.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter in the previous year, the business earned $0.47 EPS. As a group, equities analysts predict that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC increased its position in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares in the last quarter. R Squared Ltd bought a new position in Genmab A/S in the fourth quarter valued at about $93,000. Blue Trust Inc. boosted its stake in shares of Genmab A/S by 892.0% during the third quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock valued at $108,000 after purchasing an additional 3,880 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Genmab A/S by 43.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company's stock worth $113,000 after purchasing an additional 1,413 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its stake in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company's stock valued at $182,000 after buying an additional 478 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.